Abstract
Due to high prevalence multiple sclerosis is a common neurological disorder and major young adults disability cause. Despite great expectations following interferon beta and glatiramer acetate development, there is no evidence for a significant break-up in MS treatment. Furthermore, some clinical trials results seem to be dubious. For these reasons chemotherapeutic agents such as azathioprine, cyclophosphamide, cladribine, methotrexate and mitoxantrone are currently reviewed as disease modifying drugs.